CAR T and Bispecific Agents in Hematologic Malignancies

Expert perspectives and strategic insights on new and relevant clinical advances of CAR T and bispecific agents in hematologic malignancies

September 7 and 15, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

FACULTY

TBC

Agenda

Export meeting topics

View Agenda

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • CAR T Cells in Leukemias (including ALL/AML)
  • CAR T Cells in DLBCL
  • CAR T Cells in MCL and FL
  • CAR T Cells in MM
  • Bispecific Agents in Leukemias
  • Bispecific Agents in B-NHL
  • Bispecific Agents in Myeloma
  • Managing Toxicity of Bispecific Agents and CAR T Cells

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.